AMAndrea R. Mospan

Andrea R. Mospan

*This is an algorithmically generated author record based on publicly available information.

Andrea R. Mospan has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis

    by Anish Reddy, Adrielly Martins, Christopher L. Bowlus, Marlyn J. Mayo, Elizabeth J. Carey, Mark Wong, Michael Weiss, Hany Elbeshbeshy, Raymond Rubin, Velimir Luketic, et al.

    INTRODUCTION: Despite the widespread use of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC), many patients remain at risk of progression. Emerging data suggest that normalization of alkaline phosphatase (ALP) and total bilirubin (TB)—particularly when TB < 0.6 times the upper limit of normal (× ULN)—is associated with improved outcomes compared with ALP reduction to < 1.5 × ULN. This study investigated the association between ALP normalization in response to UDCA and long-term clinical outcomes in a real-world cohort of patients with PBC. METHODS: We compared complication-free survival in patients achieving an ALP > ULN and < 1.5 × ULN (adequate response) with those with an ALP ≤ ULN on UDCA monotherapy. Complication-free survival was defined as the absence of serious liver-related clinical events. Restricted mean survival time was used to quantify survival time gained. RESULTS: Patients achieving normal ALP and/or TB ≤ 0.6 × ULN demonstrated significantly improved complication-free survival compared with those with an adequate ALP response. Event-free survival was extended by 1.34 years (95% CI: 0.56, 2.11; P = 0.001) for ALP normalization alone, 3.7 years (95% CI: 3.11, 4.29; P < 0.001) for TB ≤ 0.6 × ULN, and 4.51 years (95% CI: 4.13, 4.88; P < 0.001) for those meeting both criteria. The risk of severe clinical events was reduced in patients achieving ALP normalization (hazard ratio [HR] 0.34; 95% CI: 0.15, 0.80; P = 0.01), TB ≤ 0.6 × ULN (HR 0.23; 95% CI: 0.09, 0.55; P = 0.001), or both (HR 0.14; 95% CI: 0.05, 0.38; P < 0.001). High-risk patients, defined by liver stiffness measurement ≥ 10 kPa or clinical, histological, or laboratory evidence of cirrhosis or portal hypertension, derived the greatest benefit. DISCUSSION: Achieving normal ALP and TB ≤ 0.6 × ULN is associated with significantly improved complication-free survival, particularly in high-risk patients. These findings highlight the potential of biochemical thresholds as a meaningful therapeutic goal in PBC management.


  • The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH

    by Brent A. Neuschwander‐Tetri, Heather L. Morris, Andrea R. Mospan, Feng Yu, Breda Munoz, Sheenu Abraham, Michael W. Fried, A. Sidney Barritt, Leen Al‐Sayyed, Arun J. Sanyal, et al.

    Background: Polypharmacy is common among patients with multiple comorbidities but may compromise patient health due to medication interactions, cumulative side effects and compliance challenges.Aim: Characterise the extent of polypharmacy and assess the effects of sex, liver disease severity and comorbidities in patients with metabolic dysfunction associated steatotic liver disease (MASLD) in a real‐world setting.Methods: Data from adults enrolled in TARGET‐NASH, a real‐world longitudinal observational cohort of patients with MASLD, were utilised. Reported medications were counted and relationships to disease severity, sex and insurance are described. Significant differences were identified using Chi‐square or Fisher's exact test.Results: Medication use was evaluated in 5190 adults (59% female) in the United States with the full spectrum of MASLD revealing that 90% were prescribed five or more medications and 75% were prescribed ten or more medications (63% of whom were females). Patients with cirrhosis were often prescribed nonsteroidal anti‐inflammatory drugs (64%), opioids (55%), or benzodiazepines (45%). Females were prescribed more medications than males, particularly selective serotonin reuptake inhibitors (37% vs. 20%), opioids (44% vs. 37%), proton pump inhibitors (63% vs. 52%) and benzodiazepines (41% vs. 31%).Conclusions: Polypharmacy is common among patients with MASLD. Those with cirrhosis are most affected, and women with cirrhosis are at an even greater risk. Opioid, benzodiazepine, and nonsteroidal anti‐inflammatory drug use is prevalent among patients with cirrhosis despite the known associated risks. Frequent medication use for chronic pain in patients with cirrhosis highlights the need for management plans that optimise safety balanced against therapeutic efficacy.


  • Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

    by A. Sidney Barritt, Elliot B. Tapper, Philip N. Newsome, Derek Gazis, Heather Morris, Andrea R. Mospan, Anthony Daniel Perez, Yestle Kim, Brent A. Neuschwander-Tetri, Rohit Loomba, et al.

    INTRODUCTION: Risk of cardiovascular (CV) events is estimated by the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), and the American Heart Association Predicting Risk of cardiovascular disease (CVD) EVENTs (PREVENT) equation. The applicability of these risk tools in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is uncertain. This study sought to determine the accuracy of the FRS, PCE, and PREVENT in a real-world cohort of patients with MASLD. METHODS: This analysis included US adults 30 years and older with MASLD in the TARGET-NASH study. Five to ten-year CV risk was estimated using original and recalibrated versions of the FRS and PCE, and original PREVENT equation. Discrimination among prediction models was assessed using the Harrell concordance statistic, and calibration was evaluated using a modified Hosmer Lemeshow test comparing observed and predicted CV events. Logistic regression was used to assess the contribution of liver disease to observed CV events. RESULTS: Overall, 1,090 patients were included. There was an increase in observed CV events from metabolic dysfunction-associated steatotic livers to cirrhosis. FRS demonstrated a weak ability to identify patients who went on to experience a CV event (C-statistic 0.58, 95% confidence interval 0.52–0.63) as did the American Heart Association PREVENT model (C-statistic 0.60, 95% confidence interval 0.54–0.65). Both the FRS and PCE demonstrated a significant lack of calibration ( P < 0.01), with overestimation in the highest deciles and underestimation in the lowest deciles of predicted risk. DISCUSSION: Commonly used tools to identify CV risk performed poorly in a cohort of patients with MASLD. Because CV related death is the greatest source of mortality among patients with MASLD, better risk assessment tools are required.


  • Open Access

    Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort

    by Cristian Sanchez-Torres, Ana Ramirez Tovar, Kelsey Chatman, Heather L. Morris, Feng Yu, Andrea R. Mospan, Anna Mae Diehl, Daniel H. Leung, Preeti Viswanathan, James E. Squires, et al.


  • High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort

    by A. Sidney Barritt, Feng Yu, Andrea R. Mospan, Phillip N. Newsome, Michael Roden, Heather L. Morris, Rohit Loomba, Brent A. Neuschwander-Tetri, on behalf of the TARGET-NASH investigators

    INTRODUCTION: This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort. METHODS: The new MASLD/metabolic steatohepatitis nomenclature was applied to patients enrolled with pragmatic diagnoses of nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), and NASH cirrhosis and concordance were determined between the definitions. RESULTS: Approximately 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. Approximately 1,484/1,541 (96.3%, kappa 0.974) nonalcoholic fatty liver patients (metabolic dysfunction-associated steatotic liver), 2,195/2,201 (99.7%, kappa 0.998) NASH patients (metabolic steatohepatitis), and 1,999/2,003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria. DISCUSSION: The new MASLD nomenclature is highly concordant with the previous TARGET-NASH pragmatic definitions.


  • Open Access

    Correction to: Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

    by Marlyn J. Mayo, Elizabeth Carey, Helen T. Smith, Andrea R. Mospan, Megan McLaughlin, April Thompson, Heather L. Morris, Robert Sandefur, W. Ray Kim, Christopher Bowlus, et al.


  • Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

    by Arun J Sanyal, Breda Munoz, Kenneth Cusi, A Sidney Barritt, Mark Muthiah, Andrea R Mospan, K Rajender Reddy, Roberto Firpi-Morell, Paul J Thuluvath, Kalyan Ram Bhamidimarri, et al.


  • Open Access

    Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

    by Marlyn J. Mayo, Elizabeth Carey, Helen T. Smith, Andrea R. Mospan, Megan McLaughlin, April Thompson, Heather L. Morris, Robert Sandefur, W. Ray Kim, Christopher Bowlus, et al.

    Background and Aims Patients with primary biliary cholangitis (PBC) often suffer with pruritus. We describe the impact of pruritus on quality of life and how it is managed in a real-world cohort. Methods TARGET-PBC is a longitudinal observational cohort of patients with PBC across the USA. Data include information from medical records for three years prior to the date of consent up to 5 years of follow-up. Enrolled patients were asked to complete patient-reported outcome surveys: PBC-40, 5-D itch, and the PROMIS fatigue survey. Kruskal–Wallis tests were used to compare differences in symptoms between groups. Results A total of 211 patients with completed PRO surveys were included in the current study. PRO respondents were compared with non-respondents in the TARGET-PBC population and were broadly similar. Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue. Patients reporting clinically significant pruritus were more likely to receive treatment, but 33% had never received treatment (no itch = 43.9%, mild itch = 38.3%). Conclusions The prevalence of pruritus was high in this population, and those reporting clinically significant pruritus had a higher likelihood of having advanced disease and worse quality of life. However, this study found that pruritus in PBC is under-treated. This may be due in part to ineffectiveness of current treatments, poor tolerance, or the lack of FDA-approved medications for pruritus.


  • Open Access

    Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease

    by Eduardo Castillo-Leon, Heather L. Morris, Cheryl Schoen, Jacob Bilhartz, Patrick McKiernan, Tamir Miloh, Sirish Palle, Mohammad Nasser Kabbany, Breda Munoz, Andrea R. Mospan, et al.

    Background: Pediatric non-alcoholic fatty liver disease (NAFLD) is a major public health concern. Aminotransferase (ALT) is frequently used for screening and monitoring, but few studies have reported typical patterns of ALT elevation in children. Methods: TARGET-NASH is a real-world longitudinal observational cohort of patients with NAFLD receiving care across the United States. Analyses included children enrolled between 1 August 2016, and 12 October 2020, with at least one ALT measurement after enrollment. Peak ALT was based on the first and last available record and categorized into clinical cut points: 70–250 IU/L. A chi-squared test was used to compare differences in proportions, and a Kruskal–Wallis test was used to compare the medians and distributions of continuous responses. Results: Analyses included 660 children with a median age of 13 years. Of the 660, a total of 187 had undergone a biopsy and were more likely to be Hispanic or Latino (67% vs. 57%, p = 0.02) and to have cirrhosis (10% vs. 1%, p < 0.001). The highest ALT scores ranged from 28 U/L to 929 U/L; however, these scores varied across time. The prevalence of cirrhosis or any liver fibrosis stage was most common among children with a peak ALT > 70 U/L. Conclusions: Large variability was seen in ALT among children, including many values > 250 U/L. Higher levels of ALT were associated with increased prevalence of comorbidities and more advanced stages of NAFLD. These findings support an increased need for therapeutics and disease severity assessment in children with peak ALT > 70 U/L.


  • Open Access

    Editorial: targeting liver biopsy in NAFLD—the need to expand our non‐invasive tools. Authors’ reply

    by Hannah P. Kim, Andrea R. Mospan, Michael W. Fried, Alfred Sidney Barritt, TARGET‐NASH Investigators